
|Videos|March 17, 2022
Dr. Petrylak on important updates in bladder cancer from NY GU 2022
Author(s)Urology Times staff
“There are many trials that clinicians should be aware of,” says Daniel P. Petrylak, MD.
Advertisement
In this video, Daniel P. Petrylak, MD, PhD, discusses major takeaways and ongoing research in urothelial cancer, which was presented on at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies. Petrylak is the director of genitourinary oncology, a professor of medicine and urology, co-leader of Cancer Signaling Networks, and co-director of the Signal Transduction Program at the Yale University Cancer Center in New Haven, Connecticut.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
Active surveillance use for low-risk prostate cancer reaches 93% in VA System
2
Focal therapy for prostate cancer frequently used outside guideline-supported groups
3
FDA receives NDA submission for UGN-103 in recurrent LG-IR-NMIBC
4
Ryan Flannigan, MD, highlights phase 2 data on ST-01 for chronic scrotal content pain
5









